Researchers at Columbia University took two naturally occurring DNA variants found in the SIRT6 gene of long-lived Ashkenazi Jewish centenarians and, for the first time, wrote them directly into the genome of human stem cells rather than studying them in artificial overexpression systems. The edited cells produced markedly more SIRT6 protein (without making more of its RNA) because the mutant protein sticks less tightly to a scaffolding protein called vimentin, which normally marks SIRT6 for destruction. Cells carrying the centenarian version resisted aging: they kept dividing longer, showed fewer markers of senescence, better preserved their DNA-repair machinery, and kept their “junk” jumping genes (transposons) switched off when stressed. The team then showed that a gene-therapy delivery of the centenarian SIRT6, and a seaweed extract (fucoidan) that boosts SIRT6, could partially reproduce these protective effects in cells from children with premature-aging disease. This is a preprint — not yet peer reviewed — and every result is in cultured human cells, not animals or people.
Some people sail past 100 while dodging the cancers, heart disease and frailty that fell the rest of us. A slice of that luck is written in their genes, and one of the most tantalizing clues sits in SIRT6 — a “longevity assurance” gene whose activity tracks with maximum lifespan across mammalian species and which, when boosted, extends lifespan in mice. Ashkenazi Jewish centenarians disproportionately carry a two-letter change in SIRT6 (called N308K + A313S). The obvious question has always been: does that change actually do anything useful in a real human cell?
To find out, a Columbia University team led by Yousin Suh did something more rigorous than the usual approach. Instead of flooding a cell line with extra copies of the mutant protein — a blunt method that overrides the cell’s own controls — they used CRISPR to edit the two variants into the native SIRT6 gene of human embryonic stem cells, then matured those stem cells into the connective-tissue, blood-vessel and muscle cells where aging plays out.
The first surprise: the centenarian cells contained substantially more SIRT6 protein, even though the gene was transcribed at normal levels. The extra protein wasn’t being made faster; it was being destroyed more slowly. The team traced this to vimentin, a structural filament protein that normally binds SIRT6 and helps route it for disposal. The centenarian version — specifically the single N308K change — binds vimentin more weakly, so SIRT6 accumulates. It’s an elegant, previously unknown control knob for a key aging protein.
The extra SIRT6 earned its keep under stress. Forced to divide repeatedly, centenarian cells aged more slowly. Hit with progerin — the toxic protein that causes the childhood premature-aging disease HGPS — they held onto their DNA-repair gene programs and kept transposable elements, especially LINE-1 “jumping genes,” silenced, whereas normal cells let genomic chaos loose.
Crucially, the team asked whether this could be borrowed. Delivering centenarian SIRT6 by AAV gene therapy, or dosing cells with fucoidan (a compound from bladderwrack seaweed that raises SIRT6), reproduced part of the benefit — notably suppressing LINE-1 — in cells from progeria patients. The effects on broader aging markers, however, were modest, and the whole study stops at the cell-culture stage.
Actionable Insights
Be clear-eyed: this is a mechanism paper in cultured cells, not a clinical trial, and it offers no validated human intervention.
The one consumer-relevant lever is fucoidan from Fucus vesiculosus (bladderwrack), a SIRT6-activating seaweed polysaccharide sold as a supplement. In this study it produced a dose-dependent effect: at 50 and 100 micrograms per milliliter in the culture dish, it lowered LINE-1 ORF1p/ORF2p protein — a marker of age-related genomic instability. Effect-size magnitude, stated honestly: the reduction is qualitative (Western-blot band intensity, no means/SDs or confidence intervals reported), so a Cohen’s d cannot be computed. Just as important, fucoidan did not measurably change the fraction of senescent (SA-beta-gal-positive) or dividing (Ki67-positive) cells — so even in the dish the benefit was narrow. There is also no basis here for translating a micrograms-per-milliliter dish concentration into an oral dose; supplement bioavailability of fucoidan is poor and unquantified in this work.
The durable take-home is conceptual, not pharmacological: strategies that stabilize and modestly raise SIRT6, and that specifically boost its mono-ADP-ribosylation activity (rather than the deacetylase activity most existing activators target), are a rational longevity direction worth watching. For now the practical action is to track this line of research, not to dose yourself.
Context / Source
- Open access paper: Centenarian SIRT6 variants elevate SIRT6 protein and enhance cellular senescence resistance.
- Authors / Institution / Country: Jiping Yang, Xifan Wang, HyeRim Han, Yizhou Zhu, Haiqi Chen and senior author Yousin Suh (Columbia University Irving Medical Center, New York, USA), with Lei Zhang (University of Georgia) and Paul Robbins (University of Minnesota). United States.
-
Venue / “Journal”: This is a preprint posted on Research Square on 19 June 2026.
Impact Evaluation: Research Square is a preprint platform, not a journal, so no Journal Impact Factor or CiteScore applies.